DPDPE vs Cosyntropin
Head-to-head comparison of DPDPE ([D-Pen2, D-Pen5]-enkephalin) and Cosyntropin (Cosyntropin (ACTH 1-24)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | DPDPE | Cosyntropin |
|---|---|---|
| Category | Pain Management | Pain Management |
| Full Name | [D-Pen2, D-Pen5]-enkephalin | Cosyntropin (ACTH 1-24) |
| Molecular Weight | 645.79 Da | 2933.3 Da |
| Half-Life | 15-60 minutes in plasma | ~10 min |
| Amino Acids | 5 | 24 |
| Typical Dose | 0.01-1 ug per animal | 0.25 mg IV/IM diagnostic dose|off-label headache protocols vary |
| Route | Intrathecal / intracerebroventricular | IV|IM |
| Purity | ≥98% | ≥98% |
| Studies Count | 800 | 61 |
| Research Status | Pre-clinical | Clinical research |
DPDPE Benefits
- ✓delta-opioid selectivity
- ✓improved conformational stability
- ✓analgesic receptor mapping
- ✓useful in chronic pain models
Cosyntropin Benefits
- ✓refractory migraine
- ✓anti-inflammatory signaling
- ✓headache rescue research
DPDPE Dosing
Intrathecal 0.01-1 ug per animal|Intracerebroventricular 0.01-0.5 ug per animal|In vitro 0.1-20 nM
Cosyntropin Dosing
0.25 mg IV/IM|1 mg IV/IM
DPDPE Side Effects
- ⚠sedation
- ⚠nausea-like opioid effects
- ⚠tolerance with repeated dosing
Cosyntropin Side Effects
- ⚠flushing
- ⚠nausea
Research Overview
DPDPE
DPDPE is widely cited in opioid pharmacology because it helped establish the functional role of delta-opioid receptors in pain control. Its constrained structure is also used to explore how peptide cyclization changes potency, stability, and tissue selectivity.
Cosyntropin
Cosyntropin is not a standard pain drug, but it appears in headache literature because ACTH analogs can help some patients with difficult migraine attacks. The analgesic rationale is partly tied to steroidogenic and anti-inflammatory effects.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.